Edesa Biotech Inc, a developer of novel dermatology and anorectal treatments, has secured $7 million in a Series A financing. Lumira Capital, a Canadian life sciences venture capital firm, led the round and was joined by Pharmascience Inc, Inveready Technology Investment Group and several Canadian family offices. The funds raised will be used to support the Markham, Ontario company's growth and development of its product pipeline. Edesa was founded in 2015 by its CEO, Dr. Par Nijhawan, a serial entrepreneur. In parallel with the round, Edesa licensed the Canadian rights to its anorectal products to a division of Pharmascience.